陳力瑜1 ,黃雅庭1 , 樊裕明2
- 1普瑞默生物科技股份有限公司； 2天主教耕莘醫療財團法人耕莘醫院 核子醫學科
本文已於日本第65屆核醫學會年會發表
Purpose: To assess the cost-utility of 18F-fluorodeoxyglucose (FDG) imaging versus other diagnostic tools.
Procedure: A systematic review and Bayesian network meta-analysis were conducted using studies published up to Oct 25, 2022 Incremental net benefit (INB) was estimated under a standardized cost framework using QALYs, life expectancy, and diagnostic accuracy.
Result: FDG imaging showed generally positive INBs, indicating favorable cost-effectiveness compared with most alternatives. CT-guided aspiration (CTG) had slightly higher INB due to its direct histological confirmation. In SUCRA ranking, CTG (0.685) and FDG (0.679) ranked highest. Integrated modalities like PET/CT had better cost-utility than PET or CT alone.
Conclusion: FDG imaging is a cost-effective diagnostic strategy, supporting its use in clinical decision-making.
